Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study

Rossum, Marion A J van; Fiselier, T.J.W.; Franssen, M. J. A. M.; Zwinderman, Aeilko H.; Cate, Rebecca ten; Suijlekom-Smit, Lisette W. A. van; Luijk, Wilma H. J. van; Soesbergen, R. M. Van; Wulffraat, N. M.; Oostveen, J. C. M.; Kuis, Wietse; Dijkstra, P. F.; Edè, C.; Dijkmans, B.A.C.

doi:10.1002/1529-0131(199805)41:5<808::aid-art6>3.0.co;2-t

Cited by 185 publications

(79 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CHAQ is well established for the use in children with JIA (14) and is used as one of six core response variables in clinical drug trials (15)(16)(17)(18)(19)(20). It has been validated and evaluated in the German language (21).…”

Section: Introductionmentioning

confidence: 99%

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

Halbig

Horneff

2009

Rheumatol Int

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

Halbig

Horneff

2009

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…Since the introduction of more potent treatment strategies, the evaluation of radiographic joint damage has become more prominent in the assessment of disease progression in JIA (2)(3)(4). Because one of the aims of JIA treatment is to prevent or retard joint damage, and radiographs are able to document this damage, a standardized tool for the radiologic evaluation of the lesions of the joints over time is needed.…”

mentioning

confidence: 99%

Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: Introduction of the Dijkstra composite score

Rossum¹,

Boers²,

Zwinderman³

et al. 2005

Arthritis & Rheumatism

Self Cite

View full text Add to dashboard Cite

Objective. To evaluate the sensitivity to change of a newly developed radiologic assessment tool, the Dijkstra score, and to develop a numeric composite score and progressor classification scheme to apply in juvenile idiopathic arthritis (JIA) trials.Methods. A placebo-controlled trial of sulfasalazine (SSZ) in patients with oligoarticular-and polyarticular-onset JIA yielded the data for this study. Data were obtained from 418 sets of radiographs of the clinically involved and contralateral joints (at study entry and at 6 months' followup) from 66 JIA patients. The Dijkstra score assesses the presence or absence of swelling, osteopenia, joint space narrowing, growth abnormalities, subchondral bone cysts, erosions, and malalignment. These signs were combined in the Dijkstra composite score, to assess inflammation (DI), growth (DG), and damage (DD). Progression was defined as an increase in either the DG or the DD score. Scores were evaluated among all radiographs, a standard set of films (hand, foot, and knee), and per patient. All scores were used to explore differences between the 2 treatment groups.Results. Over time, 58% of joints remained normal, 23% remained abnormal but stable, 14% showed an increase in signs, and 5% showed a decrease in signs. Of the 66 JIA patients, 12% had normal radiographic findings throughout followup, 27% showed abnormalities at some sites without change, and 61% showed change in at least 1 site. Changes in the DI, DG, and DD scores varied considerably per type of joint and occurred most frequently in joints of the standard set. DI and DG scores changed most often in the knees, while DD scores changed primarily in the hands and feet. The disease course in 8% of joints was classified as progressive. Films of SSZ-treated patients, versus the placebo group, showed less deterioration by the DD scores (P ‫؍‬ 0.04), and the disease course was more often classified as nonprogressive in the SSZ group (P ‫؍‬ 0.037). When progressors were defined as those who had at least one 1 Marion A. J. van Rossum, MD: Emma Children's Hospital AMC and Jan van Breemen Instituut,

show abstract

“…Sulphasalazine 14,15 was the commonest DMARD used in our study in contrast to Lucknow study, in which methotrexate was the commonest DMARD. 16 The limitation of application of JADI in ERA is absence of scoring for spinal involvement. Limitation of spinal mobility had high correlation with HAQ-S.…”

Section: Discussionmentioning

confidence: 99%

Study on Clinical Profile, Outcome and Hla-B27 Association in Juvenile Idiopathic Arthritis- Enthesitis Related Arthritis

Saravanan¹,

Chinnadurai²,

Vignesh³

et al. 2017

jemds

View full text Add to dashboard Cite

Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study

Abstract: The results of this first placebo-controlled study show that SSZ is effective and safe in the treatment of children with oligoarticular- and polyarticular-onset JCA, although it was not well tolerated in one-third of the patients.

Cited by 185 publications

References 24 publications

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: Introduction of the Dijkstra composite score

Study on Clinical Profile, Outcome and Hla-B27 Association in Juvenile Idiopathic Arthritis- Enthesitis Related Arthritis

Contact Info

Product

Resources

About